AZ to invest $400 million in reforestation and biodiversity

Amazon Rainforest

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030.

This includes new or expanded projects in Brazil, India, Vietnam, Ghana and Rwanda that will contribute to the company’s climate action, restore nature, promote biodiversity and build ecological and community resilience, spanning over 100,000 hectares worldwide.

The investment expands on AstraZeneca’s initial AZ Forest commitment, announced in 2020, to plant and maintain more than 50 million trees by the end of 2025. Planting has progressed in Australia, Indonesia, Ghana, the UK, the US and France, with over 300 tree species.

AZ Forest is part of AstraZeneca’s sustainability strategy, Ambition Zero Carbon, which is focused on delivering deep decarbonisation in line with the Paris Agreement goal of limiting planetary warming to 1.5°C.

The company is on track to reduce greenhouse gas emissions (GHGs) from its operations and fleet by 98% by 2026 and halve its value chain footprint by 2030. It hopes to achieve a 90% absolute emissions reduction and becoming science-based net zero by 2045 at the latest.

Through AZ Forest, the company aims to remove its residual emissions from the atmosphere from 2030 onwards.

Pascal Soriot, Chief Executive Officer of AstraZeneca, said: “The twin crises of climate change and biodiversity loss are damaging the planet and harming human health. Through AZ Forest, we are working with local communities and ecological experts to deliver reforestation at scale, as well as support biodiversity and sustain livelihoods. We are taking a science-based approach, and AZ Forest will remove around 30 million tonnes of carbon dioxide from the atmosphere over about 30 years.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free